FTC would ‘eviscerate’ attorney-client privilege, says Boehringer
01-06-2017
Mari / iStockphoto.com
The US Chamber of Commerce and the Association of Corporate Counsel (ACC) have filed an amicus curiae brief in support of Boehringer Ingelheim Pharmaceuticals in its dispute with the Federal Trade Commission (FTC).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
US Chamber of Commerce, the Association of Corporate Counsel, FTC, Boehringer Ingelheim, Barr Pharmaceuticals, pay-for-delay, competition, patent,
